Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | DNMT3A |
Variant | E240fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | DNMT3A E240fs results in a change in the amino acid sequence of the Dnmt3a protein beginning at aa 240 of 912, likely resulting in premature truncation of the functional protein (UniProt.org). E240fs has not been characterized, however, due to the effects of other truncation mutations downstream of E240 (PMID: 28872462, PMID: 26595813, PMID: 35639959), is predicted to lead to a loss of Dnmt3a protein function. |
Associated Drug Resistance | |
Category Variants Paths |
DNMT3A mutant DNMT3A inact mut DNMT3A E240fs |
Transcript | NM_022552.5 |
gDNA | chr2:g.(25248174_25248175) |
cDNA | c.(718_717) |
Protein | p.E240fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_047443594.1 | chr2:g.(25246701_25246702) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
NM_022552.5 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
NM_001320893.1 | chr2:g.(25246725_25246726) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_047443599.1 | chr2:g.(25246202_25246203) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_011532667.4 | chr2:g.(25246202_25246203) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_047443596.1 | chr2:g.(25246202_25246203) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
NM_001375819.1 | chr2:g.(25246202_25246203) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_011532664.3 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
NM_175629.2 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_017003526.1 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_005264175.6 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
NM_175629.2 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
NM_022552.4 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_047443597.1 | chr2:g.(25246202_25246203) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_017003526.2 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_047443593.1 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_011532664.2 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_017003527.2 | chr2:g.(25246202_25246203) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_047443598.1 | chr2:g.(25246202_25246203) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
XM_005264175.5 | chr2:g.(25248174_25248175) | c.(718_717) | p.E240fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|